Bioceltix S.A. (BCX.WA)

PLN 119.0

(2.59%)

EBITDA Summary of Bioceltix S.A.

  • Bioceltix S.A.'s latest annual EBITDA in 2023 was -13.22 Million PLN , down -66.73% from previous year.
  • Bioceltix S.A.'s latest quarterly EBITDA in 2024 Q2 was -4.1 Million PLN , down -0.24% from previous quarter.
  • Bioceltix S.A. reported an annual EBITDA of -8.49 Million PLN in 2022, down -58.1% from previous year.
  • Bioceltix S.A. reported an annual EBITDA of -3.95 Million PLN in 2021, down -54.98% from previous year.
  • Bioceltix S.A. reported a quarterly EBITDA of -4.1 Million PLN for 2024 Q2, down -0.24% from previous quarter.
  • Bioceltix S.A. reported a quarterly EBITDA of N/A for 2023 FY, down -66.73% from previous quarter.

Annual EBITDA Chart of Bioceltix S.A. (2023 - 2018)

Historical Annual EBITDA of Bioceltix S.A. (2023 - 2018)

Year EBITDA EBITDA Growth
2023 -13.22 Million PLN -66.73%
2022 -8.49 Million PLN -58.1%
2021 -3.95 Million PLN -54.98%
2020 -2.12 Million PLN -1.02%
2019 -1.52 Million PLN -95.59%
2018 -754.47 Thousand PLN 0.0%

Peer EBITDA Comparison of Bioceltix S.A.

Name EBITDA EBITDA Difference
BIOTON S.A. 43.89 Million PLN 130.126%
Captor Therapeutics Spolka Akcyjna -64.76 Million PLN 79.581%
Mabion S.A. 58.31 Million PLN 122.678%
Molecure S.A. -25.5 Million PLN 48.152%
NanoGroup S.A. -7.87 Million PLN -68.03%
Pharmena S.A. 33.78 Million PLN 139.148%
Poltreg S.A. -11.65 Million PLN -13.426%
Pure Biologics Spólka Akcyjna -26.07 Million PLN 49.287%
Ryvu Therapeutics S.A. -81.04 Million PLN 83.682%
Synthaverse S.A. 15.34 Million PLN 186.175%
Urteste S.A. -5.73 Million PLN -130.751%